+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
MANGALAM

Mangalam Drugs and Organics Share Price

₹28.07 +0.28 (1.01%)
66.67% Fall from 52W High

14 Aug, 2026 3:54 PM (IST)

Mangalam Drugs and Organics live price: ₹28.07. It opened at ₹29 vs previous close ₹28; intraday high/low: ₹30/₹28. The 50 & 200 DMA stand at ₹28.00/₹38.00.

Mangalam Drugs and Organics Performance

  • Today's Low
  • ₹28
  • Today's High
  • ₹30
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹84
  • Open Price₹29
  • Previous Close₹28
  • Volume48,956
  • 50 DMA₹28.00
  • 100 DMA₹30.00
  • 200 DMA₹38.00

Mangalam Drugs and Organics Chart

Investment Returns

  • Over 1 Month + 0.5%
  • Over 3 Month -6.28%
  • Over 6 Month -14.13%
  • Over 1 Year -66.08%

Smart Investing Starts Here Start SIP with Mangalam Drugs and Organics for Steady Growth!

Invest Now

Mangalam Drugs and Organics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -1.2
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 44
  • P/B Ratio
  • 0.4
  • Average True Range
  • 1.4
  • EPS
  • -24.2
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.1
  • RSI
  • 59.37
  • MFI
  • 65.87

Latest Stock News Updates

Mangalam Drugs & Organics Ltd - 532637 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper publication for declaration of Un-audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026

Mangalam Drugs & Organics Ltd - 532637 - Appointment Of Secretarial Auditor Of The Company For Term Of 5 Years Subject To Approval Of Shareholders In Ensuing 53Rd Annaul General Meeting Of The Company

Appointment of Secretarial Auditor of the Company for term of 5 years from F.Y. 2026-27 to 2030-31 subject to approval of shareholders in ensuing 53rd AGM of the Company

Mangalam Drugs & Organics Ltd - 532637 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

Appointment of Statutory Auditor for the period of 5 years subject to approval of sharehoders at ensuing 53rd Annual General meeting.

Mangalam Drugs and Organics Financials

Mangalam Drugs and Organics Technicals

EMA & SMA

Current Price
₹28.07
+ 0.28 (1.01%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹27.40
  • 50 Day
  • ₹28.00
  • 100 Day
  • ₹30.00
  • 200 Day
  • ₹38.00

Resistance and Support

28.52 Pivot Speed
  • R3 31.70
  • R2 30.80
  • R1 29.40
  • S1 27.10
  • S2 26.20
  • S3 24.80

Mangalam Drugs and Organics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-12 Quarterly Results
2026-05-14 Audited Results
2026-03-26 Others Inter-alia, to consider 1. Taking note of Resignation of Ms. Anuradha Pandey as Company Secretary & Compliance Officer. 2. Appointment of Ms. Shweta Patel as Company Secretary & Compliance Officer.
2026-02-06 Others
2026-01-15 Quarterly Results

Mangalam Drugs and Organics Shareholding Pattern

64.24%
35.65%
0.11%
0%

About Mangalam Drugs and Organics

Mangalam Drugs and Organics engaged in the manufacture and sale of Active Pharmaceutical Ingredients (API) for various therapeutic segments viz. Anti Malaria, Anti-Retrovirat, Anti-Hypertensive etc. View More
  • NSE Symbol
  • MANGALAM
  • BSE Symbol
  • 532637
  • ISIN
  • INE584F01014

Similar Stocks to Mangalam Drugs and Organics

Mangalam Drugs and Organics FAQs

Mangalam Drugs and Organics share price is ₹28 As on 16 August, 2026 | 17:31

The Market Cap of Mangalam Drugs and Organics is ₹44.4 Cr As on 16 August, 2026 | 17:31

The P/E ratio of Mangalam Drugs and Organics is -1.2 As on 16 August, 2026 | 17:31

The PB ratio of Mangalam Drugs and Organics is 0.4 As on 16 August, 2026 | 17:31

The 52 week High & Low of Mangalam Drugs and Organics is ₹84.2/₹22.8 respectively As on 16 August, 2026 | 17:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23